Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 4/20 | 0.43 |
| ▸ | BTK | Q06187 | 7/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 13/20 | 0.41 |
| ▸ | ITK | Q08881 | 7/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | LYN | P07948 | 1/20 | 0.39 |
| ▸ | TEC | P42680 | 1/20 | 0.39 |
| ▸ | TXK | P42681 | 1/20 | 0.39 |
| ▸ | BMX | P51813 | 1/20 | 0.39 |
| ▸ | CD69 | Q07108 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30931281 | 1.00 | JAK3 (0.43) | JAK3BTKCYP1A2LRRK2EGFR | |
| SCHEMBL27240955 | 0.93 | JAK3 (0.44) | JAK3BTKEGFRITKJAK2 | |
| SCHEMBL27240768 | 0.92 | BTK (0.43) | JAK3BTKEGFRITK | |
| SCHEMBL30931287 | 0.92 | BTK (0.43) | JAK3BTKEGFRITK | |
| SCHEMBL27240805 | 0.92 | BTK (0.45) | JAK3BTKLRRK2EGFRITK | |
| SCHEMBL27240829 | 0.91 | JAK3 (0.41) | JAK3BTKEGFRITK | |
| SCHEMBL27240838 | 0.91 | JAK3 (0.41) | JAK3BTKEGFRITK | |
| SCHEMBL27240973 | 0.91 | JAK3 (0.41) | JAK3BTKEGFRITK | |
| SCHEMBL27240933 | 0.91 | LRRK2 (0.43) | JAK3BTKLRRK2EGFRITK | |
| SCHEMBL30931264 | 0.90 | EGFR (0.45) | JAK3BTKEGFRITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190849-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | TYRA BIOSCIENCES, INC. | 2024-06-13 | — | — | US | claimed |
| US-20240190849-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | TYRA BIOSCIENCES, INC. | 2024-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190849-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | DPYD, TYMP, TYMS | JAK3 1800/4885BTK 2153/4885CYP1A2 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.